Care Management
The Promise and Questions of Aducanumab
Biogen’s new Alzheimer’s drug may be changing the treatment landscape, but lingering questions remain. More
Commentary
“Drug Costs”
17 result(s)
Cost Management
Changes to CVS Caremark template formularies effective January 1, 2021 continue our legacy of innovation as well as delivering value and quality care — helping clients save money... More
Briefing
Drug Pipeline
After many years of failure, there is hope for potential treatments that could slow disease progression for those with Alzheimer's Disease. If approved, Biogen's... More
Feature
Drug Pipeline
CVS Health provides an early look at some key Breakthrough Therapies expected to be reviewed by the FDA in 2020 as well as the associated cost implications and expected approval... More
Feature
Drug Pipeline
New drugs to treat migraine are approaching approval and could bring relief for many patients, but they portend higher costs. Ongoing monitoring and appropriate utilization... More
Feature
Cost Management
Payors are projected to save on per-member-per-month costs from strategic formulary removals designed to help mitigate the effect of high-cost and hyperinflationary drugs More
Briefing
Cost Management
New GAO report shows that rebates negotiated on behalf of payors may help control premiums and provides further proof of the value PBMs bring to payors and members. More
Commentary
Public Policy
Proposed HHS rule would eliminate rebates PBMs negotiate for Part D plans and MCOs, and may eventually affect all plans. Manufacturers would retain 15% of rebates currently... More
Briefing
Cost Management
The Guaranteed Net Cost model guarantees average net spend per prescription, after discounts and rebates, for each distribution channel. More
Feature
Cost Management
CVS Health responded to the Administration's Blueprint on lowering drug costs and highlighted what the company does to control costs. We also recommended things the... More
Commentary